Sector News

Gilead and Novo Nordisk expand collaboration for NASH clinical study

March 20, 2021
Life sciences

Gilead Sciences and Novo Nordisk are expanding their clinical collaboration in non-alcoholic steatohepatitis (NASH) to conduct a larger trial later this year.

The move comes after a previous study, investigating Novo Nordisk’s semaglutide alone and in combination with Gilead’s cilofexor and/or firsocostat in patients suffering from NASH with mild to moderate fibrosis, reported positive data.

The larger Phase IIb study will assess the safety and efficacy of semaglutide and a fixed-dose combination of cilofexor and firsocostat, alone and in combination in patients with compensated cirrhosis (F4) due to NASH.

The four-arm double-blind, placebo-controlled study aims to enrol around 440 patients, with recruitment expected to begin in the second half of this year.

Post-hoc analyses of the previous study identified statistically significant improvements in hepatic steatosis and liver injury in the combination treatment arms compared with semaglutide alone.

Around 5% to 14% of the subjects across all groups withdrew from the study due to adverse events.

Novo Nordisk executive vice-president and development head Martin Holst Lange said: “NASH is a disease with a high unmet medical need, as no drugs are currently approved to treat this potentially life-threatening condition.

“Building on the positive results from our proof-of-concept trial, we hope together with Gilead to demonstrate the potential for semaglutide with cilofexor and firsocostat to help people living with NASH.”

Semaglutide, a GLP-1 receptor agonist, has been approved for the treatment of type 2 diabetes but is yet to receive the green light from a regulatory authority for treating patients with NASH.

Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat are also not approved.

Gilead Sciences recently signed an agreement with Merck to develop and commercialise long-acting treatments for HIV.

By Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach